Protein Kinase Inhibitors: all 15,038 studies that test it

Page 83 of 151. Open to participants first (2,480), then studies with results posted, then the rest; newest registration first within each.

• Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory ComplicationsCompletedNCT05104723Phase 1/2
• Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver TransplantTerminatedNCT05103904Phase 2
• Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg FormulationsStatus unknownNCT05103891Phase 1
• The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 MutationActive, not recruitingNCT05102292Phase 1/2
• Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based TherapyCompletedNCT05101629Phase 2
• Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform NeurofibromasActive, not recruitingNCT05101148Phase 1
• A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone LymphomaActive, not recruitingNCT05100862Phase 3
• Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB000928 in Participants With Impaired Renal Function and HemodialysisCompletedNCT05099445Phase 1
• StrataPATH™ (Precision Indications for Approved Therapies)TerminatedNCT05097599Phase 2
• Study to Evaluate the Mass Balance and Biotransformation of [14C]SHR1459 in Healthy Adult Male VolunteersStatus unknownNCT05095337Phase 1
• The Efficacy and Safety of HLX208 in Adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (ECD) With BRAF V600E MutationActive, not recruitingNCT05092815Phase 2
• The Efficacy of HLX208 (BRAF V600E Inhibitor) for Refractory Primary Brain Tumors With BRAF Mutation After First-line TreatmentStatus unknownNCT05092802Phase 2
• TD-0903 Pharmacokinetics Study in Healthy Participants With Supplemental OxygenationCompletedNCT05091723Phase 1
• Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to MethotrexateStatus unknownNCT05090410Phase 3
• Preventing High Blood Sugar in People Being Treated for Metastatic Breast CancerActive, not recruitingNCT05090358Phase 2
• Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort StudyActive, not recruitingNCT05089916Phase 2
• Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted GraftActive, not recruitingNCT05088356Phase 1
• Clinical Study of SPH3348 Tablets, a C-Met Inhibitor, in Patients with Advanced Solid TumorsCompletedNCT05088070Phase 1
• Toripalimab Combined With Anlotinib in Unresectable Locally Advanced or Metastatic Acral Malignant MelanomaStatus unknownNCT05087602Phase 2
• Efficacy, Safety and Immunological Evaluation of Tofacitinib in the Treatment of Primary Sjogren's SyndromeStatus unknownNCT05087589Phase 2
• A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547Status unknownNCT05086666Phase 1/2
• Salvage Surgery Following Downstaging of Advanced Non-small Cell Lung Cancer by Targeted Therapy (SDANT)Status unknownNCT05085054Phase 2
• PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell LymphomaTerminatedNCT05083208Phase 1
• Tocilizumab Versus Baricitinib in Patients With Severe COVID-19CompletedNCT05082714Not applicable
• Brazilian Lung Immunotherapy StudyCompletedNCT05081674Phase 2
• Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS TumorsTerminatedNCT05081180Phase 1
• Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)WithdrawnNCT05080621Phase 1/2
• COVID-19 VaccinE Response in Rheumatology PatientsCompletedNCT05080218Phase 4
• ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung AdenocarcinomasStatus unknownNCT05079022Phase 1/2
• A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC PatientsActive, not recruitingNCT05078931Phase 2
• FOLFIRINOX + Elraglusib + Losartan In Pancreatic CancerActive, not recruitingNCT05077800Phase 2
• A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast CancerActive, not recruitingNCT05077449Phase 3
• Open-label Study of Surufatinib in Japanese PatientsCompletedNCT05077384Phase 1/2
• A Study of Lazertinib (JNJ-73841937) in Healthy ParticipantsCompletedNCT05076877Phase 1
• Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast CancerStatus unknownNCT05076695Phase 2
• Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC PatientsActive, not recruitingNCT05074810Phase 1/2
• A Study to Evaluate Relative Bioavailability and Food-Effect of HA121-28 Tablet B in Healthy SubjectsCompletedNCT05072535Phase 1
• A Study of SKLB1028 in Patients With Advanced Solid TumorStatus unknownNCT05072522Phase 1
• Evaluation of TRILACICLIB in Chinese Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC) for Chemotherapy-induced Myelosuppression, Antitumor Effects of Combination Regimens, and Safety in a Real-world StudyCompletedNCT05071703Phase 4
• Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALLTerminatedNCT05071482Phase 4
• Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric CancerStatus unknownNCT05070598Phase 2
• Study of Afatinib in Advanced Cutaneous Squamous Cell CarcinomaActive, not recruitingNCT05070403Phase 2
• A Study to Investigate the Drug-drug Interactions (DDIs) Between SKLB1028 and Midazolam in Healthy SubjectsCompletedNCT05070195Phase 1
• A Study to Investigate the Drug-drug Interactions (DDIs) of SKLB1028 With Itraconazole, Gemfibrozil or Rifampicin in Healthy SubjectsStatus unknownNCT05069870Phase 1
• JAK Inhibition in Food AllergyCompletedNCT05069831Phase 1
• Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine TherapyActive, not recruitingNCT05069038Phase 2
• A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of INCB054707CompletedNCT05068466Phase 1
• A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOxStatus unknownNCT05068206Phase 2
• Efficacy & Safety of Nintedanib in Patients With Progressive Fibrosing Coal Mine Dust-Induced Interstitial Lung DiseaseWithdrawnNCT05067517Phase 3
• ACALA-R In Predominantly Demyelinating IgM Mediated NeuropathyActive, not recruitingNCT05065554Phase 2
• Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast CancerTerminatedNCT05065411Phase 3
• A Phase II Clinical Trial to Evaluate HLX208 in Advanced Non-small Cell Lung Cancer Patients With BRAF V600 MutationStatus unknownNCT05065398Phase 2
• Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in PIK3CA-mutated HER2+ Advanced BC (ALPHABET)TerminatedNCT05063786Phase 3
• Treatment of Non Severe Hemophagocytosis Lymphohistiocytosis With ITACITINIBCompletedNCT05063110Phase 2
• Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer PatientsSuspendedNCT05062889Phase 2
• A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)Status unknownNCT05061147Phase 1/2
• A Study to Evaluate Drug-Drug Interaction of Larotinib With Itraconazole and Rifampin in Healthy Adult ParticipantsCompletedNCT05057949Phase 1
• A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaActive, not recruitingNCT05057494Phase 3
• Efficacy and Safety of Baricitinib in Patients With Moderate and Severe COVID-19Status unknownNCT05056558Phase 3
• A Phase I Study of XZP-3621 in Chinese Patients With ALK or ROS1 Rearrangement Non-small Cell Lung CancerCompletedNCT05055232Phase 1
• GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast CancerCompletedNCT05054751Phase 3
• RVU120 (SEL120) in Patients With Relapse/Refractory Metastatic or Advanced Solid TumorsTerminatedNCT05052255Phase 1/2
• A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell LymphomaCompletedNCT05051891Phase 3
• To Explore the Efficacy and Safety of Camrelizumab Combined With SHR1020 in the Treatment of Advanced MelanomaStatus unknownNCT05051865Phase 2
• A Study to Evaluate the Bioavailability of Fedratinib When Administered in Different Ways to Healthy Adult ParticipantsCompletedNCT05051553Phase 1
• A Trial to Evaluate the Effect of Delgocitinib on the Heart Rhythm of Healthy PeopleCompletedNCT05050279Early Phase 1
• Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous CellStatus unknownNCT05049681Phase 3
• Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic FunctionWithdrawnNCT05048368Phase 1
• Masitinib in Patients With Symptomatic Mild to Moderate COVID-19Status unknownNCT05047783Phase 2
• A Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3811 Tablets in Patients With Advanced Malignant TumorsStatus unknownNCT05046847Phase 1
• Pharmacokinetics Study of Famitinib Malate Capsules in Healthy SubjectsCompletedNCT05046808Phase 1
• Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung CancerWithdrawnNCT05045404Phase 2
• A Study of HS-10342 in Chinese Patients With HR+/HER2- Advanced and/or Metastatic Breast CancerStatus unknownNCT05044988Phase 2
• Duvelisib Following Chimeric Antigen Receptor T-Cell TherapyActive, not recruitingNCT05044039Phase 1
• A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell CarcinomaActive, not recruitingNCT05043922Phase 2
• Ursodeoxycholic Acid Prevents Total Parenteral Nutrition CholestasisStatus unknownNCT05043194Not applicable
• Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCCActive, not recruitingNCT05043090Phase 3
• Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid LeukemiaStatus unknownNCT05042531Not applicable
• Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast CancerActive, not recruitingNCT05041842Phase 2
• Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal AdenocarcinomaActive, not recruitingNCT05041153Early Phase 1
• Study of the Effect of Fostamatinib Upon Cutaneous Inflammation in the Setting of Hidradenitis SuppurativaCompletedNCT05040698Phase 2
• A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line TherapyWithdrawnNCT05039736Phase 2
• A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP).TerminatedNCT05039515Phase 2
• Atezolizumab and Cabozantinib for the Treatment of Recurrent GlioblastomaActive, not recruitingNCT05039281Phase 1/2
• Anlotinib Combined With TQB2450 (PD-L1 Inhibitor) in the Treatment of Advanced Esophageal Squamous Cell Carcinoma(ESCC)Active, not recruitingNCT05038813Phase 2
• Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.Active, not recruitingNCT05038735Phase 3
• A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSLCompletedNCT05036577Phase 1
• A Study of NB004 as Monotherapy or Combination Therapy in Patients With Advanced Solid TumorsTerminatedNCT05036291Phase 1
• Anlotinib Combined With mXELIRI as Second-line Treatment of Advanced Colorectal CancerStatus unknownNCT05035914Phase 1/2
• Study of Ruxolitinib Cream in Children With Atopic DermatitisCompletedNCT05034822Phase 1
• Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic CancerCompletedNCT05034627Phase 1
• Food Effect and Mass Balance Study of XZP-3621 TabletsCompletedNCT05034120Phase 1
• Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy SubjectsCompletedNCT05030857Phase 1
• Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy with Hypomethylating AgentsCompletedNCT05030675Phase 1
• A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010)Active, not recruitingNCT05030506Phase 1
• Trial of Surufatinib Combined With Toripalimab in the Treatment of Peritoneal Metastatic Carcinoma of Gastrointestinal or Primary Peritoneal CancerStatus unknownNCT05030246Phase 2
• Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial CarcinomaStatus unknownNCT05030077Phase 2
• Phase III Study on HMPL-523 for Treatment of ITPCompletedNCT05029635Phase 3
• Apatinib Combined With Chemotherapy Versus Chemotherapy in Second-line Gastric Cancer Receiving Prior Anti-PD-1 TherapyStatus unknownNCT05029453Phase 4
• A Clinical Study of TQB3824 in Subjects With Advanced CancerStatus unknownNCT05028218Phase 1

← Protein Kinase Inhibitors overview